Does RUCAPARIB CAMSYLATE Cause Malignant neoplasm progression? 1,162 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,162 reports of Malignant neoplasm progression have been filed in association with RUCAPARIB CAMSYLATE (Rubraca). This represents 14.1% of all adverse event reports for RUCAPARIB CAMSYLATE.
1,162
Reports of Malignant neoplasm progression with RUCAPARIB CAMSYLATE
14.1%
of all RUCAPARIB CAMSYLATE reports
69
Deaths
139
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RUCAPARIB CAMSYLATE?
Of the 1,162 reports, 69 (5.9%) resulted in death, 139 (12.0%) required hospitalization, and 1 (0.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUCAPARIB CAMSYLATE. However, 1,162 reports have been filed with the FAERS database.
What Other Side Effects Does RUCAPARIB CAMSYLATE Cause?
Fatigue (2,494)
Nausea (2,219)
Decreased appetite (787)
Constipation (763)
Diarrhoea (759)
Vomiting (759)
Asthenia (660)
Adverse event (571)
Carbohydrate antigen 125 increased (562)
Dysgeusia (558)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RUCAPARIB CAMSYLATE Alternatives Have Lower Malignant neoplasm progression Risk?
RUCAPARIB CAMSYLATE vs RUFINAMIDE
RUCAPARIB CAMSYLATE vs RUPATADINE
RUCAPARIB CAMSYLATE vs RUXOLITINIB
RUCAPARIB CAMSYLATE vs SABRIL
RUCAPARIB CAMSYLATE vs SACCHAROMYCES CEREVISIAE